Resolvin D1 and D2 inhibit tumour growth and inflammation via modulating macrophage polarization

Plastic polarization of macrophage is involved in tumorigenesis. M1‐polarized macrophage mediates rapid inflammation, entity clearance and may also cause inflammation‐induced mutagenesis. M2‐polarized macrophage inhibits rapid inflammation but can promote tumour aggravation. ω‐3 long‐chain polyunsaturated fatty acid (PUFA)‐derived metabolites show a strong anti‐inflammatory effect because they can skew macrophage polarization from M1 to M2. However, their role in tumour promotive M2 macrophage is still unknown. Resolvin D1 and D2 (RvD1 and RvD2) are docosahexaenoic acid (DHA)‐derived docosanoids converted by 15‐lipoxygenase then 5‐lipoxygenase successively. We found that although dietary DHA can inhibit prostate cancer in vivo, neither DHA (10 μmol/L) nor RvD (100 nmol/L) can directly inhibit the proliferation of prostate cancer cells in vitro. Unexpectedly, in a cancer cell‐macrophage co‐culture system, both DHA and RvD significantly inhibited cancer cell proliferation. RvD1 and RvD2 inhibited tumour‐associated macrophage (TAM or M2d) polarization. Meanwhile, RvD1 and RvD2 also exhibited anti‐inflammatory effects by inhibiting LPS‐interferon (IFN)‐γ‐induced M1 polarization as well as promoting interleukin‐4 (IL‐4)‐mediated M2a polarization. These differential polarization processes were mediated, at least in part, by protein kinase A. These results suggest that regulation of macrophage polarization using RvDs may be a potential therapeutic approach in the management of prostate cancer.